Vikas Kharbanda

Partner

Head, Healthcare and Life Sciences Practice, Middle East

India, Saudi Arabia, United Arab Emirates

Vikas advises leading players in the Healthcare sector on growth strategies, operational effectiveness and digital transformations.

Education

Indian Institute of Management Calcutta
Master Business of Administration
Indian Institute of Technology Delhi
Bachelor of Technology

Past Experience

IBM Global Business Services
Senior Manager, Strategy & Transformation Practice

Vikas is a Partner with Arthur D. Little, based in Dubai, and leads the Healthcare & Life Sciences practice in the Middle East.

Over the past few years, Vikas has been working with several leading Healthcare service providers in the Middle East and Asia on their growth and expansion strategies.

In his current and previous roles, Vikas has also worked with Hospital operators on improving their operations effectiveness while enhancing patient experience.

Vikas also works extensively with clients, advising them in their digitalization strategies and leveraging technology to improve both patient experiences and operational effectiveness.

Vikas has been the author of several articles on diverse topics related to digitalization in Healthcare & the life sciences industry and has presented at several industry events.

Advancing biotechnology & genomics in Saudi Arabia
Advancing biotechnology & genomics in Saudi Arabia
Best practice strategies to develop the sector & maximize its impact
Catalyzing digital health in India
Catalyzing digital health in India
Critical pathways for user adoption & driving the next wave of transformational use cases
A bold vision for India’s digital health
A bold vision for India’s digital health
A digital revolution driven by the Indian consumer awaits
Building the next generation of emergency care systems
Pursuing excellence: What’s next for finance in healthcare?
Managing competition, price and access
High medicine prices impose a burden on national healthcare systems, where pharmaceuticals account for a significant share of spending, especially for countries in the early stages of maturity in the pharma sector. Competition authorities have expressed concerns that access to affordable, innovative drugs may be at risk due to high prices, market withdrawals or other business strategies, along with national governments’ limited bargaining power against pharma companies.

Vikas is a Partner with Arthur D. Little, based in Dubai, and leads the Healthcare & Life Sciences practice in the Middle East.

Over the past few years, Vikas has been working with several leading Healthcare service providers in the Middle East and Asia on their growth and expansion strategies.

In his current and previous roles, Vikas has also worked with Hospital operators on improving their operations effectiveness while enhancing patient experience.

Vikas also works extensively with clients, advising them in their digitalization strategies and leveraging technology to improve both patient experiences and operational effectiveness.

Vikas has been the author of several articles on diverse topics related to digitalization in Healthcare & the life sciences industry and has presented at several industry events.

Advancing biotechnology & genomics in Saudi Arabia
Advancing biotechnology & genomics in Saudi Arabia
Best practice strategies to develop the sector & maximize its impact
Catalyzing digital health in India
Catalyzing digital health in India
Critical pathways for user adoption & driving the next wave of transformational use cases
A bold vision for India’s digital health
A bold vision for India’s digital health
A digital revolution driven by the Indian consumer awaits
Building the next generation of emergency care systems
Pursuing excellence: What’s next for finance in healthcare?
Managing competition, price and access
High medicine prices impose a burden on national healthcare systems, where pharmaceuticals account for a significant share of spending, especially for countries in the early stages of maturity in the pharma sector. Competition authorities have expressed concerns that access to affordable, innovative drugs may be at risk due to high prices, market withdrawals or other business strategies, along with national governments’ limited bargaining power against pharma companies.

More About Vikas
  • Indian Institute of Management Calcutta
    Master Business of Administration
  • Indian Institute of Technology Delhi
    Bachelor of Technology
  • IBM Global Business Services
    Senior Manager, Strategy & Transformation Practice